12.11.2021 07:00 | AGL | Participation at Jefferies healthcare conference | Reach |
11.11.2021 07:00 | AGL | Parsortix system showcased at NCRI Festival | Reach |
10.11.2021 17:40 | AGL | Issue of Equity | RNS |
02.11.2021 07:00 | AGL | Change of Adviser | RNS |
21.10.2021 17:25 | AGL | Issue of Equity | RNS |
15.10.2021 17:45 | AGL | Issue of Equity | RNS |
30.09.2021 16:02 | AGL | Issue of Equity | RNS |
30.09.2021 07:00 | AGL | Interim Results | RNS |
27.09.2021 07:00 | AGL | Parsortix demonstrates ability to isolate CTCs | Reach |
22.09.2021 07:00 | AGL | Study shows use of Parsortix to assess PD-L1 | Reach |
20.09.2021 07:00 | AGL | Parsortix enables gene expression analysis in mPCa | Reach |
07.09.2021 07:00 | AGL | Notice of Interim Results and Webcast | RNS |
24.08.2021 07:00 | AGL | Director/PDMR Shareholding | RNS |
09.08.2021 07:00 | AGL | Study highlights superior performance of Parsortix | Reach |
06.08.2021 13:17 | AGL | Issue of Equity | RNS |
03.08.2021 15:13 | AGL | Issue of Equity | RNS |
28.07.2021 07:00 | AGL | Contract secured for bespoke assay development | RNS |
09.07.2021 07:00 | AGL | Harvesting CTCs from brain metastasis patients | Reach |
07.07.2021 18:34 | AGL | Director/PDMR Shareholding | RNS |
02.07.2021 10:45 | AGL | Issue of Equity | RNS |
30.06.2021 15:44 | AGL | Result of AGM | RNS |
25.06.2021 07:00 | AGL | Result of Accelerated Bookbuild | RNS |
24.06.2021 18:28 | AGL | Accelerated bookbuild to raise up to £20m | RNS |
18.06.2021 11:42 | AGL | Annual General Meeting update | RNS |
18.06.2021 07:00 | AGL | ctDNA and CTCs have differences in EGFR mutations | Reach |
04.06.2021 07:00 | AGL | Update on submission for FDA clearance | Reach |
01.06.2021 07:00 | AGL | Potential to prevent breast cancer relapse | RNS |
20.05.2021 07:00 | AGL | Parsortix demonstrates oesophageal cancer utility | Reach |
19.05.2021 16:37 | AGL | Exercise of options and total voting rights | RNS |
11.05.2021 07:00 | AGL | Parsortix study uncovers targets in TNBC patients | Reach |
30.04.2021 11:22 | AGL | Exercise of options and total voting rights | RNS |
29.04.2021 07:00 | AGL | Preliminary Results | RNS |
26.04.2021 07:00 | AGL | Ovarian cancer study patient enrolment completed | RNS |
19.04.2021 14:05 | AGL | Second Price Monitoring Extn | RNS |
19.04.2021 14:00 | AGL | Price Monitoring Extension | RNS |
19.04.2021 11:05 | AGL | Second Price Monitoring Extn | RNS |
19.04.2021 11:00 | AGL | Price Monitoring Extension | RNS |
16.04.2021 07:00 | AGL | First large-scale pharma services contract secured | RNS |
15.04.2021 16:10 | AGL | Notice of Preliminary Results and Webcast | RNS |
12.04.2021 07:00 | AGL | ANGLE's Parsortix system showcased at AACR 2021 | Reach |
30.03.2021 07:00 | AGL | Global launch of clinical services laboratories | RNS |
04.03.2021 07:00 | AGL | Update on submission for FDA clearance | RNS |
18.02.2021 07:00 | AGL | Parsortix-harvested CTCs uncover novel biomarker | Reach |
08.02.2021 07:00 | AGL | Parsortix: Dynamic assessment of patient response | Reach |
29.01.2021 07:00 | AGL | Parsortix demonstrates high capture rate of CTCs | Reach |
26.01.2021 13:00 | AGL | Holding(s) in Company | RNS |
20.01.2021 07:00 | AGL | Research confirms high performance of Parsortix | Reach |
12.01.2021 07:00 | AGL | Change of Auditor | Reach |
05.01.2021 07:00 | AGL | Issue of Equity | RNS |